Skip to main content
Full access
Clinical and Research Reports
Published Online: 7 October 2019

What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

Abstract

Objective:

A growing interest in functional neurological disorders (FND) has led to the development of specialized clinics. This study aimed to better understand the structure and role of such clinics.

Methods:

Data were retrospectively collected from clinical records at three national referral centers, two specifically for motor FND and one for FND in general. Data were for 492 consecutive patients referred over a 9- to 15-month period: 100 from the United Kingdom clinic, 302 from the Swiss clinic, and 90 from the Canadian clinic. Data included symptom subtype and duration, comorbid pain and fatigue, disability, and treatment recommendations.

Results:

The mean age of the 492 patients was 44 years, and most (73%) were female. Most had a prolonged motor FND (mean symptom duration of 6 years); 35% were not working because of ill health, 26% received disability benefits, and up to 38% required a care giver for personal care. In the Swiss cohort, 39% were given a diagnosis of another somatic symptom disorder rather than an FND diagnosis. Pain was common in the United Kingdom (79%) and Canada (56%), as was fatigue (48% and 47%, respectively). Most patients (61%) were offered physiotherapy; referral to neuropsychiatry or psychology differed across centers (32%−100%).

Conclusions:

FND specialty clinics have an important role in ensuring correct diagnosis and appropriate treatment. Most patients with motor FND require specialized neurophysiotherapy. Patients readily accepted an integrated neuropsychiatric approach. Close collaboration between FND clinics and acute neurology facilities might improve early detection of FND and could improve outcomes.
Recent years have seen a resurgence in interest in functional neurological disorders (FND), fueled by the recognition of their frequency and the profound disability that they cause (1). Increased understanding of the underlying neurobiology (24) has developed hand in hand with new clinical management strategies and a growing evidence base for rehabilitative treatments (5, 6). Yet a gap exists in clinical practice because only a few clinical facilities worldwide have dedicated expertise and resources to coordinate the diagnosis and treatment of FND within a specialist service (79).
This study explored the utility of specialist FND clinics, based on experience from programs developed in the United Kingdom (2008) Switzerland (2016) and Canada (2018). A critical view is offered on how such services may be optimally developed in the future.

Experiences of Three New Referral Centers

United Kingdom

Our specialist functional movement disorder (FMD) neurology-led clinic (first established at the National Hospital for Neurology and Neurosurgery and now relocated to St George’s University Hospital) is a tertiary service, with most referrals coming from other neurologists. The primary aims of the clinic are to provide a second opinion when there is diagnostic uncertainty, to provide patients and their families with information and education about the diagnosis, and to triage patients into appropriate treatment services depending on their symptoms and comorbidities. Over time, the clinic has expanded to include four neurologists and direct links to an FND-specialist neurophysiotherapy program, outpatient neuropsychiatry, clinical psychology, and inpatient multidisciplinary rehabilitation (MDT). We aim to offer a follow-up appointment after completion of treatment and then try to arrange local follow-up in primary care, general neurology, or local mental health services, depending on need. In practice, we often struggle to discharge patients from our service because they report benefit from ongoing contact with us, even if we are not providing active treatment. We are currently developing a specialist nurse role to aid transition back to local services. This person could also provide a point of contact for patients and local care providers in times of crisis or to deal with queries that do not require face-to-face follow-up.

Switzerland

On the background of a merger of the Psychosomatic Unit within the Neurology Department, we opened a new outpatient service at Bern University Hospital, a bilingual tertiary center receiving referrals from all Switzerland. Neurologists and general practitioners were informed that they could refer suspected FND cases for diagnosis and treatment. Three neurologists receive the new referrals to confirm the diagnosis and offer interdisciplinary treatment. The neurologists also do in-house consultation for individuals suspected of having FND who are hospitalized. Interdisciplinary treatment consists of 1-hour follow-up appointments with the neurologist alone or in joint sessions with the psychologist; in these sessions cognitive-behavioral therapy (CBT) is provided, based on published workbooks specific for FND (10). In parallel, individual sessions with a physiotherapist and individual or group sessions with an occupational therapist are organized. A weekly interdisciplinary meeting allows all disciplines to share information in order to set goals and milestones for patients following therapy and plan discharge. When long-term psychotherapy is needed, patients are further referred to private-practice psychologists or psychiatrists; patients are informed from the beginning that we do not have the capacity for long-term treatment. Biannual neurology follow-up after discharge is routinely proposed. A close collaboration with the local pain clinic, psychosomatic medicine specialists, and rehabilitation hospitals allows referral of patients with comorbidities from somatic symptom disorders or those in need of prolonged inpatient integrated care.

Canada

On the background of a long history of experience with FMD at the Toronto Western Hospital Movement Disorders Clinic, a dedicated treatment program was started for this patient population. This is a tertiary referral center, with most referrals coming from community neurologists. The treatment program coincided with the recruitment of an academic neuropsychiatrist dedicated to motor FND. Prior to this, the role of the clinic was in diagnosis of FND and referral to community physiotherapy or neuropsychiatry within the same institution or instructions to the primary care physician to make a local referral for physiotherapy. In April 2018, an Integrated Clinic was started to develop an approach that replaced this referral-based model. In this clinic the patients are treated simultaneously by the neurologist, neuropsychiatrist, and physiotherapist in a rehabilitation-based model for six visits in biweekly, 45-minute appointments. All patients undergo a neuropsychiatric evaluation after diagnosis and prior to beginning therapy, reflecting an integrated approach.
To better understand the function and role of specialized FND clinics, we collected routine clinical practice data from these three national referral centers.

Methods

Retrospective data were collected from clinical records and notes. Details of data collection are presented in Table 1. Demographic and clinical data were for 492 consecutive patients referred to the three clinics over a 9- to 15-month period: 100 from the United Kingdom clinic, 302 from the Swiss clinic, and 90 from the Canadian clinic.
TABLE 1. Data collection for a study of three specialized clinics for patients with functional neurological disorders (FND)
VariableUnited KingdomSwitzerlandCanada
Opening of the clinicSeptember 2008October 2016November 2017
Study inclusion criteriaConsecutive patients with a confirmed functional movement disorder (FMD)Consecutive patients with suspected FNDPatients with FMD referred to neuropsychiatry
Study periodApril 30, 2017–February 9, 2018November 1, 2016–February 1, 2018January 1, 2018–December 30, 2018
Method of data collectionChart reviewChart reviewChart review
Diagnosis assessment4 neurologists3 neurologists10 neurologists
Duration of neurological first assessment1 hour1.5 hours1 hour
Duration of neurological follow-up30 minutes1 hour30 minutes
Interdisciplinary follow-upDepending on the treatment program, with a neurologist, a physiotherapist, or a neuropsychiatristJoint sessions of 30 minutes with a neurologist, then 30 minutes with a psychologist, and then 30 minutes with both together; independent individual sessions with a physiotherapist and an occupational therapistIntegrated clinic, with 45 minutes with a neurologist, a neuropsychiatrist, and a physiotherapist
Duration of interdisciplinary treatment5 days to 12 weeks, depending on the program3 months to a maximum of 6 months, with weekly physiotherapy and monthly joint sessions3 months, with biweekly visits
NetworkInpatient multidisciplinary rehabilitation, outpatient psychology and neuropsychiatry, day-case pain management program, 5-day specialist physiotherapy programPain clinic, psychosomatic medicine specialists, inpatient multidisciplinary rehabilitation in rehabilitation clinicsCommunity physiotherapy, outpatient neuropsychiatry

Results

Demographic and clinical data are presented in Table 2. The mean age of the 492 patients was 44 years, and most (73%) were female. The socioeconomic impact of their health condition was notable, with a mean of 35% of patients not working because of ill health and 26% receiving disability benefits. In addition, a proportion of patients (10%–38%) needed a care provider for daily activities.
TABLE 2. Characteristics of three cohorts of patients seen at specialized clinics for patients with functional neurological disorders (FND)a
 United KingdomSwitzerlandCanada
CharacteristicN%N%N%
Sociodemographic      
 N of patients in cohort10030290
 Age (M±SD)42.5±14.2 44±15 46±16 
 Sex      
  Male 20 37 25
  Female 80 63 75
 Employment status      
  Paid employment (full- or part-time) 19 48 23
  Retired or not working (nonmedical reasons) 7 17 6
  Not working because of ill health 39 25 40
  Student 7 6 8
  Volunteer work 10 1
  Unknown 27 4 21
 Benefits and social help      
  Receives disability benefit 34 15 28
  Receives unemployment benefitNR  4NR 
  RefugeeNR  2NR 
 Assistance for personal care      
  Paid caregiver (social services funded) 14NR  1
  Unpaid caregiver (family or friends) 24NR  9
  No assistance needed 37NR  67
  Unknown 25NR  23
Diagnostic      
 Final diagnosis of FND100100183 90100
 Motor FND (ICD-10-CM, F44.4) 466938910
  Gait 18201167
  Predominant weakness 28492733
 Abnormal movement (ICD-10-CM, F44.4) 4843238190
  FMD tremor 8NR 1517
  FMD facial symptom 5NR 78
  FMD dystonia 5NR 910
  FMD fixed dystonia 3NR 11
  FMD jerks 3NR  7
  FMD parkinsonism0NR  1
  FMD chorea 1NR 0
  FMD mixed symptoms 24NR 4247
 Sensory (ICD-10-CM, F44.5)019100
 Psychogenic nonepileptic seizures (PNES) (ICD-10-CM, F44.6)023130
 Mixed (ICD-10-CM, F44.7) (FMD+PNES) 192916 18
 Other 600
  Pain without motor symptoms on examination 4NR  1
  Dizziness without motor symptoms 1NR 0
  Parkinson’s disease with functional overlay 1NR  2
 FND with persistent pain as a significant problem 79NR  56
 FND with fatigue as a significant problem 48NR  47
 Duration and presentation of symptoms      
  Mean duration (M±SD years)6.7±6.1 4±6 7.4±8.1 
  Median duration (years)5.0 2.3 4.0 
 Paroxysmal presentation of FND symptom 25NR  29
a
FMD=functional movement disorder, NR=not reported.
The mean symptom duration was 6 years across all centers, with local differences: a mean of 6.7 and 7.4 years for the United Kingdom and Canada, respectively, and 4.8 years for Switzerland.
The clinics in the United Kingdom and Canada were set up specifically for FMD (including limb weakness). The Swiss cohort, which also included patients with nonconfirmed suspected FND, had greater diversity of dominant symptom, although 61% had a motor dominant presentation (weakness, 38%, and abnormal movement, 23%). Pain was common in the United Kingdom (79%) and Canada (56%), as was fatigue (48% and 47%, respectively). In the Swiss cohort, 39% received a primary diagnosis other than FND, and among them pain, fatigue, or another somatic symptom disorder were the main complaints (68%) (for further details, see Table S1 in online supplement). Additionally, in the Swiss cohort, 13% were diagnosed as having psychogenic nonepileptic seizures.
Regarding treatment, of the 492 patients, 301 (61%) were offered physiotherapy, either alone or as a component of a multidisciplinary program: 48 (48%) of the 100 patients in the United Kingdom cohort (specialized physiotherapy following consensus recommendations [11] for 22 [22%] and within a multidisciplinary program for 24 [24%]), 39 (43%) of the 90 patients in the Canada cohort, and 214 (71%) of the 302 patients in the Swiss cohort.
Recommendations for psychotherapy were more variable. In the United Kingdom, 8 (8%) were referred for psychotherapy as a stand-alone treatment and 24 (24%) as part of MDT (total 32%). In Switzerland, 196 (65%) were referred for psychotherapy, either stand-alone or as part of an MDT program. In Canada, all patients were referred to neuropsychiatry, a proportion (N=11, 12%) of whom participated in the Integrated Clinic (for multidisciplinary treatment). Another 9 (10%) already had a psychiatrist, whom they continued to see for treatment of comorbid psychiatric conditions, not specifically for treatment of their FND.

Discussion and Lessons Learned

Lesson 1

FND is a syndrome with multiple comorbidities, and specialized neurological evaluation is useful for specific patients.

Because FND is highly prevalent (12), all neurologists need to be familiar with and effective at making the diagnosis, discussing it with the patient, and offering appropriate treatment. Local policies should be established to recommend which patients should be referred to specialized FND clinics.
One key role of FND clinics is to help resolve diagnostic uncertainty (13), especially in cases of co-occurrence of FND and other neurological disorders (particularly epilepsy and movement disorder). FND clinics can provide additional time and expertise for diagnostic explanation. This can be a useful service for patients who are uncertain about the diagnosis after initial neurological consultation (14, 15). Many patients seemed to hear a clear diagnosis for the first time in our clinics and often expressed relief, which highlights difficulties among neurologists in delivering the diagnosis (16).
FND clinics can also provide time and expertise to triage patients into appropriate treatment, paying specific attention to individuals with comorbidities such as fatigue and pain, which have a worse prognosis (17).

Lesson 2

A high percentage of patients require physical rehabilitation, and specialized services are needed.

More than half of the patients in this sample (61%) were offered physiotherapy (alone or as part of a multidisciplinary treatment), reflecting evidence that physical rehabilitation can be effective for a proportion of people with motor FND (18) without prominent comorbidities (19, 20). The practicalities of where and how this treatment is delivered are still a challenge, because some community- and hospital-based rehabilitation services may lack the necessary experience and resources to help patients with FND (21). Developing specialist allied health services for individuals with FND will help provide outreach and support to community services, thereby improving skills and confidence in treating persons with FND.

Lesson 3

Neuropsychiatric evaluation and treatment specific to FND are needed.

Triage to neuropsychiatry and psychology differed in the three clinics. The policy in the United Kingdom clinic is that neurologists ask patients about their psychiatric history and current mental health, but not all patients are referred to see a psychiatrist. This reflects the aim of trying to maintain efficiency within the service by avoiding a “one size fits all” pathway. Such flexibility in how treatment is delivered is important to optimize outcomes and engagement. Some patients who are initially reluctant or skeptical about psychological treatment may be more amenable after starting physiotherapy.
In Switzerland, a high percentage of patients accepted referrals to psychotherapy, which might be explained by three factors. First, the diagnosis of FND and the proposal to see a psychologist was made by neurologists dually trained in neurology and psychosomatic medicine (training in psychosomatic medicine targets mostly interpersonal communication techniques). Second, the patient was informed that the aim of seeing a psychologist was to start treatment (CBT-inspired therapy) and not to look for a psychiatric diagnosis that could explain the symptoms. Third, the psychologist was integrated into the team, and joint sessions were offered with both the neurologist and the psychologist to avoid the implicit message that the neurologist was “passing off” the patient to psychology.
In Canada, all patients accepted referrals to neuropsychiatry. Therapeutic delivery of a clear diagnosis by the neurologist, who also explained that the neuropsychiatrist was a clinic-affiliated FND treatment expert, likely facilitated this very high acceptance rate. Neuropsychiatric assessment and subsequent treatment involved framing of FND as a complex illness in which brain, body, and mind represent an integrated whole, readily influenced by internal factors and the outside environment, rather than a manifestation of a “psychological problem.” Psychiatric comorbidities and relevant psychosocial or physical stressors were appropriately managed but were considered perpetuating rather than causal factors for FND.
Integrated neuropsychiatric skills are needed for both diagnostic and treatment purposes (22). Referral to an external psychiatry or psychology facility reinforces a dualistic view that the condition is not neurological but rather psychiatric and increases the possibility of misunderstanding and poor uptake of potentially useful treatment.

Lesson 4

Earlier detection and treatment of FND are needed.

Patients with long illness duration (6 years) were seen in our clinics, and the illness had a high socioeconomic impact. Patients seen in the Swiss clinic tended to have a shorter duration of symptoms (median of 2.3 years), which may reflect inclusion of patients who were hospitalized in the acute phase of their symptoms, whereas the clinics in the United Kingdom and Canada saw only individuals referred as outpatients.
Patients’ understanding of the diagnosis was often poor, which may have contributed to the long duration of symptoms and illness (perpetuating factor). Even if it appeared clear from the notes that referring practitioners had already made and communicated the diagnosis, the patient had often not understood the diagnosis except in a negative way: “They told me it was all in my head.” A factor that may have contributed to patients’ negative impression of previous consultations is that many patients were not offered any treatment after diagnosis, which may have given them the impression that health care services did not believe that there was anything seriously wrong.
There is a need for FND clinics to work closely with acute neurology services or to accommodate early consultation for patients with recent onset of symptoms. Improving the way in which the diagnosis is communicated in the emergency department and implementing a liaison team from the FND clinic to see patients while they are in the emergency department could improve diagnostic understanding and help flag specific patients for treatment, which may improve attendance rates at FND clinics (8) or other treatments.
The data presented in this report have a number of limitations, including retrospective design, different inclusion criteria across centers, and treatment recommendations biased toward local availability and expertise.

Conclusions

Prospective and outcome data are needed to better refine the goals and understand the added value of FND clinics in international health care systems. However, our retrospective data and clinical experience suggest that specialized FND clinics integrated in neurology departments are needed and will help improve the clinical care of FND patients.

Supplementary Material

File (appi.neuropsych.19040083.ds001.pdf)

References

1.
Espay AJ, Aybek S, Carson A, et al: Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 2018; 75:1132–1141
2.
Edwards MJ, Adams RA, Brown H, et al: A Bayesian account of “hysteria”. Brain 2012; 135:3495–3512
3.
Lehn A, Gelauff J, Hoeritzauer I, et al: Functional neurological disorders: mechanisms and treatment. J Neurol 2016; 263:611–620
4.
Voon V, Cavanna AE, Coburn K, et al: Functional neuroanatomy and neurophysiology of functional neurological disorders (conversion disorder). J Neuropsychiatry Clin Neurosci 2016; 28:168–190
5.
Nielsen G: Physical treatment of functional neurologic disorders. Handb Clin Neurol 2016; 139:555–569
6.
Goldstein LH, Mellers JDC: Psychologic treatment of functional neurologic disorders. Handb Clin Neurol 2016; 139:571–583
7.
Jacob AE, Smith CA, Jablonski ME, et al: Multidisciplinary clinic for functional movement disorders (FMD): 1-year experience from a single centre. J Neurol Neurosurg Psychiatry 2018; 89:1011–1012
8.
Perez DL, Young SS, King JN, et al: Preliminary predictors of initial attendance, symptom burden, and motor subtype in a US functional neurological disorders clinic population. Cogn Behav Neurol 2016; 29:197–205
10.
Williams C, Kent C, Smith S, et al: Overcoming Functional Neurological Symptoms: A Five Area Approach. Totnes, United Kingdom, Hodder Arnold, 2011
11.
Nielsen G, Stone J, Matthews A, et al: Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry 2015; 86:1113–1119
12.
Carson A, Lehn A: Epidemiology. Handb Clin Neurol 2016; 139:47–60
13.
Stone J, Reuber M, Carson A: Functional symptoms in neurology: mimics and chameleons. Pract Neurol 2013; 13:104–113
14.
Monzoni CM, Duncan R, Grünewald R, et al: How do neurologists discuss functional symptoms with their patients: a conversation analytic study. J Psychosom Res 2011; 71:377–383
15.
Carson AJ, Stone J, Warlow C, et al: Patients whom neurologists find difficult to help. J Neurol Neurosurg Psychiatry 2004; 75:1776–1778
16.
Carson A, Lehn A, Ludwig L, et al: Explaining functional disorders in the neurology clinic: a photo story. Pract Neurol 2016; 16:56–61
17.
Glass SP, Matin N, Williams B, et al: Neuropsychiatric factors linked to adherence and short-term outcome in a US functional neurological disorders clinic: a retrospective cohort study. J Neuropsychiatry Clin Neurosci 2018; 30:152–159
18.
Nielsen G, Buszewicz M, Stevenson F, et al: Randomised feasibility study of physiotherapy for patients with functional motor symptoms. J Neurol Neurosurg Psychiatry 2017; 88:484–490
19.
Nielsen G, Ricciardi L, Demartini B, et al: Outcomes of a 5-day physiotherapy programme for functional (psychogenic) motor disorders. J Neurol 2015; 262:674–681
20.
Jacob AE, Kaelin DL, Roach AR, et al: Motor retraining (MoRe) for functional movement disorders: outcomes from a 1-week multidisciplinary rehabilitation program. PM R 2018; 10:1164–1172
21.
Edwards MJ, Stone J, Nielsen G: Physiotherapists and patients with functional (psychogenic) motor symptoms: a survey of attitudes and interest. J Neurol Neurosurg Psychiatry 2012; 83:655–658
22.
Perez DL, Keshavan MS, Scharf JM, et al: Bridging the great divide: what can neurology learn from psychiatry? J Neuropsychiatry Clin Neurosci 2018; 30:271–278

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 79 - 84
PubMed: 31587627

History

Received: 2 April 2019
Revision received: 27 May 2019
Revision received: 24 June 2019
Revision received: 13 July 2019
Accepted: 16 July 2019
Published online: 7 October 2019
Published in print: Winter 2020

Keywords

  1. Functional Neurological Disorders
  2. Functional Movement Disorders

Authors

Details

Selma Aybek, M.D. [email protected]
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).
Sarah C. Lidstone, M.D., Ph.D.
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).
Glenn Nielsen, Ph.D.
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).
Lindsey MacGillivray, M.D., Ph.D.
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).
Claudio L. Bassetti, M.D.
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).
Anthony E. Lang, M.D.
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).
Mark J. Edwards, M.D.
The Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland (Aybek, Bassetti); the Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and University of Toronto (Lidstone, Lang); the Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St. George’s University of London (Nielsen, Edwards); and the Department of Psychiatry, University Health Network and University of Toronto (MacGillivray).

Notes

Send correspondence to Dr. Aybek ([email protected]).

Competing Interests

The authors report no financial relationships with commercial interests.

Funding Information

National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272:
Medical Research Councilhttp://dx.doi.org/10.13039/501100000265:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschunghttp://dx.doi.org/10.13039/501100001711: PP00P3_176985
Supported by the Swiss National Science Foundation (grant PP00P3_176985 to Dr. Aybek), a grant from the National Institute for Health Research (to Dr. Nielsen), and a grant from the Medical Research Council (to Dr. Edwards).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share